Li Mei, Huang Xiao-Guang, Yang Zhi-Ning, Lu Jia-Yang, Zhan Yi-Zhou, Xie Wen-Jia, Zhou Dong-Jie, Wang Li, Zhu Di-Xia, Lin Zhi-Xiong
1 Department of Radiation Oncology, Cancer Hospital, Shantou University Medical College, Shantou, Guangdong, China.
2 Department of Radiation Oncology, Shantou Central Hospital, Shantou, Guangdong, China.
Br J Radiol. 2016 Sep;89(1065):20150621. doi: 10.1259/bjr.20150621. Epub 2016 Jul 4.
To investigate the need for elective neck irradiation (ENI) to nodal Level IB in patients with nasopharyngeal carcinoma (NPC) with negative Level IB lymph nodes (IB-negative) treated by intensity-modulated radiotherapy (IMRT).
We conducted a Phase 2 prospective study in 123 newly diagnosed IB-negative patients with NPC treated by IMRT, who met at least 1 of the following criteria: (1) unilateral or bilateral Level II involvement with 1 of the following: Level IIA involvement or any Level II node ≥2 cm/with extracapsular spread; (2) ≥2 unilateral node-positive regions. Bilateral Level IB nodes were not contoured as part of the treatment target and treated electively. Level IB regional recurrence rate; pattern of treatment failure; 3-year overall survival (3y-OS), 3-year local control (3y-LC) and 3-year regional control (3y-RC) rates; toxicities; and dosimetric data for planning target volumes, organs at risk, Level IB and submandibular glands (SMGs) were evaluated.
Two patients developed failures at Level IB (1.6%). The 3y-LC, 3y-RC and 3y-OS rates were 93.5%, 93.5% and 78.0%, respectively. Bilateral Level IB received unplanned high-dose irradiation with a mean dose (Dmean) ≥50 Gy in 60% of patients. The average Dmean of bilateral SMGs was approximately 53 Gy.
ENI to Level IB may be unnecessary in IB-negative patients with NPC treated by IMRT. A further Phase 3 study is warranted.
Based on the results of this first Phase 2 study, we suggest omitting ENI to Level IB in Ib-negative patients with NPC with extensive nodal disease treated by IMRT.
探讨调强放射治疗(IMRT)治疗的鼻咽癌(NPC)患者中,IB区淋巴结阴性(IB阴性)时对IB区进行选择性颈部照射(ENI)的必要性。
我们对123例新诊断的接受IMRT治疗的IB阴性NPC患者进行了一项2期前瞻性研究,这些患者至少符合以下标准之一:(1)单侧或双侧II区受累,且符合以下情况之一:IIA区受累或任何II区淋巴结≥2 cm/有包膜外扩散;(2)≥2个单侧淋巴结阳性区域。双侧IB区淋巴结未被勾画为治疗靶区的一部分,也未进行选择性治疗。评估IB区局部复发率、治疗失败模式、3年总生存率(3y-OS)、3年局部控制率(3y-LC)和3年区域控制率(3y-RC)、毒性以及计划靶区、危及器官、IB区和下颌下腺(SMG)的剂量学数据。
2例患者出现IB区失败(1.6%)。3y-LC、3y-RC和3y-OS率分别为93.5%、93.5%和78.0%。60%的患者双侧IB区接受了非计划的高剂量照射,平均剂量(Dmean)≥50 Gy。双侧SMG的平均Dmean约为53 Gy。
IMRT治疗的IB阴性NPC患者可能无需对IB区进行ENI。有必要进一步开展3期研究。
基于这项首个2期研究的结果,我们建议在接受IMRT治疗的有广泛淋巴结疾病的IB阴性NPC患者中,省略对IB区的ENI。